Compare JACK & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JACK | CBIO |
|---|---|---|
| Founded | 1951 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.8M | 557.8M |
| IPO Year | 1994 | N/A |
| Metric | JACK | CBIO |
|---|---|---|
| Price | $12.36 | $19.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $21.93 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 951.5K | 247.8K |
| Earning Date | 05-13-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,465,314,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.04 | $279.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.92 | $8.72 |
| 52 Week High | $27.74 | $20.68 |
| Indicator | JACK | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 68.18 |
| Support Level | $8.92 | $10.89 |
| Resistance Level | $20.96 | $20.58 |
| Average True Range (ATR) | 0.80 | 1.77 |
| MACD | 0.47 | 0.12 |
| Stochastic Oscillator | 95.66 | 83.31 |
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants across various states in the United States of America. Its core business includes the Jack in the Box hamburger chain, known for a broad menu that features hamburgers, tacos, sandwiches, salads, and breakfast items. The company also operates the Del Taco brand, which offers a variety of both Mexican and American favorites such as burritos and fries. These foods are available with the option of customization as per customer requirements. The company also offers catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two reportable operating segments, of which, Jack in the Box generates maximum revenue for the company.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.